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Abstract  
 
The phosphatidylinositide 3-kinases (PI3K) and mammalian target of rapamycin-1 (mTOR1) are 
two key targets for anti-cancer therapy. Predicting the response of the PI3K/AKT/mTOR1 
signalling pathway to targeted therapy is made difficult because of network complexities. 
Systems biology models can help explore those complexities but the value of such models is 
dependent on accurate parameterisation. Motivated by a need to increase accuracy in kinetic 
parameter estimation, and therefore the predictive power of the model, we present a 
framework to integrate kinetic data from enzyme assays into a unified enzyme kinetic model. 
We present exemplar kinetic models of PI3K and mTOR1, calibrated on in vitro enzyme data 
and founded on Michaelis-Menten (MM) approximation. We describe the effects of an 
allosteric mTOR1 inhibitor (Rapamycin) and ATP-competitive inhibitors (BEZ2235 and 
LY294002) that show dual inhibition of mTOR1 and PI3K. We also model the kinetics of 
phosphatase and tensin homolog (PTEN), which modulates sensitivity of the PI3K/AKT/mTOR1 
pathway to these drugs. Model validation with independent data sets allows investigation of 
enzyme function and drug dose dependencies in a wide range of experimental conditions. 
Modelling of the mTOR1 kinetics showed that Rapamycin has an IC50 independent on ATP 
concentration and Rapamycin is selective inhibitor of mTOR1 substrates S6K1 and 4EBP1: it 
retains 40% of mTOR1 activity relative to 4EBP1 phosphorylation and inhibits completely S6K1 
activity. For the dual ATP-competitive inhibitors of mTOR1 and PI3K, LY294002 and BEZ235, we 
derived the dependence of the IC50 on ATP concentration that allows prediction of the IC50 at 
different ATP concentrations in enzyme and cellular assays. Comparison of the drug 
effectiveness in enzyme and cellular assays showed that some features of these drugs arise 
from signalling modulation beyond the on-target action and MM approximation and require a 
systems-level consideration of the whole PI3K/PTEN/AKT/mTOR1 network in order to 
understand mechanisms of drug sensitivity and resistance in different cancer cell lines. We 
suggest that using these models in systems biology investigation of the PI3K/AKT/mTOR1 
signalling in cancer cells can bridge the gap between direct drug target action and the 
therapeutic response to these drugs and their combinations.  
 
Keywords: kinetic modelling; PI3K; mTOR1; PTEN; Rapamycin; BEZ235  
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1. Introduction 
 
The kinases, the mammalian target of Rapamycin (mTOR1/2), and phosphoinositide-3 
kinase (PI3K) are central hubs in the regulation of anti-apoptotic and proliferation signalling in 
the PI3K/PTEN/AKT/mTOR1/S6K1 network (Cully et al., 2006; Laplante and Sabatini, 2012). 
Given this regulatory role, they are considered pivotal targets in cancer drug therapy (Zoncu et 
al., 2011). The fundamental goal in targeted therapy drug development is high therapeutic 
efficacy, and this efficacy is characterised not only by inhibition of the targeted protein but also 
by the response of the whole signalling network to on-target inhibition.  
Predicting the response of the PI3K/PTEN/AKT/mTOR1/S6K1 signalling network to 
targeted therapy is made difficult because of pathway complexities. These complexities include 
multiple extra- and intra-cellular stimuli, extensive crosstalk with other signalling pathways, 
multiple feedforwards and feedbacks within pathways, and genetic aberrations in specific 
proteins (Chandarlapaty, 2012). These complexities and protein mutations within the pathway 
combine in ways that can induce pathway hyperactivation in cancer cells and lead to de novo 
and acquired drug resistance in different cancers (Wang et al., 2009). 
The schematic in Fig. 1 shows the pathways involved in the activation of the 
PI3K/PTEN/AKT/mTOR1/S6K1 network by receptor tyrosine kinase (RTK) signalling. Upstream 
stimulation of the network results in recruitment and phosphorylation of PI3K, which then 
phosphorylates phosphatidylinositol 4,5 bisphosphate (PIP2) to phosphatidylinositol 3,4,4-
triphosphate (PIP3). The second lipid messenger PIP3 in turn recruits downstream proteins to 
the plasma membrane and this leads to phosphorylation of AKT and PDK1 kinases. Phosphatase 
and tensin homolog deleted on chromosome ten (PTEN) dephosphorylates PIP3 into PIP2. A 
normal function of PI3 kinase and phosphatase PTEN strictly control the response of AKT 
signalling to RTK stimuli (Goltsov et al., 2012). The most common aberrations in the PI3K/PTEN 
cycle, observed in 80% of cancers, are loss of PTEN and/or PIK3CA mutations that cause 
activation of the PI3K/PTEN/AKT/mTOR1/S6K1 signalling network independently of RTK signals, 
which can lead to tumourigenesis and drug resistance (Nik-Zainal et al., 2016; Stemke-Hale et 
al., 2008).  
mTOR acts as a key downstream integrator of PI3K/PTEN/AKT signalling and the 
serine/threonine protein kinase assembles into two complexes, mTOR1 and mTOR2: mTOR1 is 
a major regulator of cap-dependent translation and elongation via phosphorylation of 4EBP1 
and S6K1 respectively (Siddiqui and Sonenberg, 2015); mTOR2 phosphorylates AKT(Ser437) 
(Cully et al., 2006). Besides kinase catalytic domains, mTOR has several domains (FAT, HEAT, 
FAT, FRB) acting as structural scaffolding for different subunits of the mTOR1 and mTOR2 
complexes (Raptor, Rictor, PRAS40, and mSLT8) which regulate its binding to 
substrate/activator, catalytic activity and localisation (Yang et al., 2013). Phosphorylation of 
S6K1 at multiple phospho-sites by both mTOR1 and PDK1 (Phosphoinositide-dependent kinase-
1) forms feedforward and feedback loops in the PI3K/PTEN/AKT/mTOR1/S6K1 pathway (Fig. 1). 
These feedback loops, together with crosstalk with the MAPK pathway and mTOR1 
autoregulation through protein-protein interactions, mean that drug action must account for 
system-scale properties. That is, the response of the output signal is defined by properties of 
the whole signalling network, since it is the whole network that modulates functioning of the 
specific drug targeted proteins.  
Multiple drugs targeting this pathway are in clinical practice or preclinical development 
(Kalachand et al., 2011; Markman et al., 2010), and here we focus on Rapamycin and BEZ235 
(Mita et al., 2016). We also consider LY294002 because of its common use in studies of the 
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response of PI3K/AKT pathway to inhibition in different cancer cell lines (Vlahos et al., 1994; 
Walker et al., 2000). Rapamycin is a mTOR-targeting molecule isolated from bacteria and used 
as an antifungal and immunosuppressive drug (Laplante and Sabatini, 2012; Wang et al., 2009). 
In preclinical studies, Rapamycin has shown anti-tumour effects against various tumour types 
including breast cancer, glioblastoma, rhabdomyosarcoma by controlling cell survival, 
angiogenesis and proliferation (Laplante and Sabatini, 2012; Wang et al., 2009). Temsirolimus, 
a rapamycin rapalog, was approved to treat progressive renal cell carcinoma in the clinic (Hudes 
et al., 2007). Although Rapamycin rapalogs have shown promising antitumour effects in 
preclinical studies, most of the clinical trial outcomes were disappointing. The existence of 
several feedback loops in the PI3K/AKT/mTOR pathway may have played an important role in 
the limitation of Rapamycin in addition to its inadequacy in blocking mTORC2 (Harrington et al., 
2004; Jacinto et al., 2004; Yu et al., 2011). 
Both PI3K and mTOR belong to the PI3K-related kinase (PIKK) family, and so both might  
be inhibited by the same ATP competitive inhibitors, resulting in dual activity against both 
targets. BEZ235 is a potent PI3K/mTOR dual inhibitor that blocks both class I PI3K and mTOR1/2 
through competition for the ATP-binding sites of these enzymes (Maira et al., 2008). In vitro and 
in vivo studies have shown its high anti-proliferative activities in neoplastic cells as well as a 
reduction in the phosphorylation level of AKT and its downstream proteins (Jebahi et al., 2014; 
Maira et al., 2008; Serra et al., 2008). BEZ235 is currently in phase 1/2 clinical trials and is being 
tested against a number of solid tumours including breast, endometrial, renal and pancreatic 
tumours. Results show good dose toleration but limited clinical response as a monotherapy or 
in combination with other drugs (Bendell et al., 2015).  
LY294002 is an ATP competitive inhibitor of PI3K (p110α/β) and, although it is not in 
clinical practice due its toxicity, it is widely used in numerous cell line studies to inhibit the 
PI3K/AKT pathway. Studies have revealed that LY294002 is not specifically selective for PI3K and 
can have off-target effects, and mTOR is among those off-targets impacted by LY294002 (DNA-
dependent kinase (DNA-PK), casein kinase  (2CK2), GSK3β) (Gharbi et al., 2007; Toral-Barza et 
al., 2005). Accordingly, some of these off-target effects of LY294002 relate to the 
PI3K/AKT/mTOR pathway and might contribute to the overall inhibition effect observed upon 
cell treatment. Toral-Barza et al. (Toral-Barza et al., 2005) showed that LY294002 is a PI3K/mTOR 
dual inhibitor that blocks PI3K and mTOR kinase through an ATP-competitive mechanism. 
Studies on the PI3K/PTEN/AKT/mTOR1/S6K1 pathway reveal clear discrepancies among 
drug efficacy readouts at the target, pathway and cellular levels for different cancer cell lines 
(Hassan et al., 2014; Santiskulvong et al., 2011; Shoji et al., 2012). These observed discrepancies 
are likely due to a mix of the complexity of the signalling network and its mutations together 
with fundamental differences in enzyme kinetics in various cellular environments. In particular, 
intracellular conditions in cancer cells may be significantly different to experimental conditions 
in enzymatic assays, e.g. substrate and cofactor concentrations (Acker and Auld, 2014). To 
inform the comparison of drug efficacies obtained in enzymatic and cellular assays, and to 
combine the data derived from these assays, we need data on protein and inhibition kinetics in 
different cancer cells in different conditions. In general, key intracellular conditions cannot be 
modelled in enzymatic assays but these can be modelled in in silico experiments using enzyme 
kinetic models that describe enzyme and inhibitor properties in a wide region of environmental 
conditions. 
This paper provides a systems biology framework to integrate kinetic data from 
enzymatic and cellular assays into a unified kinetic model. Fig. 2 shows a schematic of this 
framework, where data describing enzyme activity following drug action may be combined with 
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enzyme kinetic data to predict the IC50 for drugs in different cellular conditions.  Integration of 
various kinds of experimental data is motivated by a need to increase accuracy in kinetic 
parameter estimation and therefore the predictive power of the systems biology models. 
Accurate estimations of enzyme kinetic parameters are needed to ‘bridge the gaps in systems 
biology’ (Cvijovic et al., 2014) by reducing model uncertainty. A well calibrated model can be 
used to help explain the observed discrepancies of enzyme function and drug effects in different 
experimental conditions, in different cellular environment as well as in analysis of enzyme 
mutation effects of drug action in various cellular lines. 
Previous models of enzyme kinetics that are based on detailed kinetic mechanisms and 
integration of a wide range of  in vitro experimental data can be found e.g. for Rho GTPases 
(Goryachev and Pokhilko, 2006), the adenine nucleotide translocase (Metelkin et al., 2009), and 
S6K1 protein kinase (Keshwani and Harris, 2008). We extend these approaches by 
demonstrating the incorporation of experimental data that characterises enzymatic response 
to drug action to inform model construction. Here, as an exemplar use of this framework we 
present kinetic models of purified enzymes PI3K, mTOR1 and PTEN that describe their catalysis 
mechanisms. We apply these models to investigate the effects of allosteric (Rapamycin) and 
ATP-competitive (BEZ235, L294002) inhibitors of mTOR1 and PI3K. We use Michaelis-Menten 
(MM) approximation in our model formulation combined with in vitro protein assay data on 
enzyme kinetics to calibrate and then validate the models. In line with the increasing 
publications devoted to the expansion of MM approximation and its application in metabolic 
and signalling network investigation  (Cornish-Bowden, 2013; Schnell, 2014; Tummler et al., 
2014) we test whether the kinetics of these kinases and phosphatase can be described in MM 
approximation and reproduce such indicators as kinetic curves, inhibition constants, dose 
dependencies and IC50 values. We compare drug activities in purified protein assays and those 
in cancer cell populations in order to determine those drug properties which can be described 
by MM kinetics and those properties that lie beyond this approximation and depend on an 
understanding of the whole signalling network response. We also discuss an application of this 
comparative analysis to translation of in vitro data on drug activity to therapeutic drug efficacy.  
 
2. Methods 
 
The schematic of our approach is shown in Fig. 2. For model development, calibration and 
validation we used two types of experimental data: dependencies of enzyme activity on 
substrate concentrations measured in the absence and presence of drugs and dose 
dependencies of enzyme inhibition on drug concentrations. The developed approach allows us 
to integrate kinetic experimental data obtained under different experimental conditions. 
Integrating data increases model reliability and accuracy with respect to kinetic parameter 
estimation because of an increase in the set of experimental points used in that estimation over 
separate experimental data sets (Cornish-Bowden, 2014). Moreover, we also make use of 
molecular structural data on enzyme-substrate and enzyme-drug complexes to support model 
formulation. Specifically, involvement of these structural data can serve to discriminate among 
different candidate mechanisms of drug action, e.g. inhibition of enzyme activity or substrate 
affinity. We can validate the model on independent data sets and then this validated model may 
be used to investigate enzyme functions in experimental conditions beyond those used in its 
construction.  
Fitting of experimental data was carried out using the constrained nonlinear optimization 
method running Matlab (MathWorks Inc.). Standard errors and confident intervals of the kinetic 
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parameters obtained in fitting were estimated using the bootstrap method (Draper and Smith, 
2014; Efron and Tibshirani, 1994). In the bootstrap procedure we used a resampling process for 
the n residues  
𝒆𝒆 = 𝒀𝒀𝑒𝑒𝑒𝑒𝑒𝑒 − 𝒀𝒀𝑚𝑚𝑚𝑚𝑚𝑚  ,  
where 𝒀𝒀𝑒𝑒𝑒𝑒𝑒𝑒 and  𝒀𝒀𝑚𝑚𝑚𝑚𝑚𝑚 are vectors of the experimental data and the best fitted model results; 
e is a vector of the residues of dimension N corresponding to a number of experimental points. 
Then we generate M bootstrap residues vector 𝒆𝒆𝑖𝑖∗ where each element is chosen from the 
elements of the residue vector 𝒆𝒆 with probability 1/n. At the next step of the bootstrap 
procedure, the model is fitted against bootstrap samples   
𝒀𝒀𝑒𝑒𝑒𝑒𝑒𝑒,𝑖𝑖∗ = 𝒀𝒀𝑒𝑒𝑒𝑒𝑒𝑒 + 𝒆𝒆𝑖𝑖∗ 
to define the estimates of M samples of kinetics parameters  𝒌𝒌𝑖𝑖.  
As an estimate of kinetic parameter 𝑘𝑘𝑙𝑙  we use the median of M bootstrap samples for 
parameter 𝑘𝑘𝑙𝑙  obtained in the fitting procedure. As a bootstrap confidence interval (CI) we 
calculate the percentile confidence interval (𝑘𝑘𝑙𝑙,𝑙𝑙𝑚𝑚𝑙𝑙 ;  𝑘𝑘𝑙𝑙,𝑢𝑢𝑒𝑒), where 𝑘𝑘𝑙𝑙,𝑙𝑙𝑚𝑚𝑙𝑙 and 𝑘𝑘𝑙𝑙,𝑢𝑢𝑒𝑒 are 2.5th and 
97.5 percentile of the distribution of 𝑘𝑘𝑙𝑙  obtained  in the bootstrap process (Efron and Tibshirani, 
1994). We compared these estimate of parameters 𝑘𝑘𝑙𝑙  with the mean values 𝑘𝑘𝑙𝑙�  of M bootstrap 
samples and the standard normal confidence interval (𝑘𝑘𝑙𝑙� − 1.96 ∙ 𝑆𝑆𝑆𝑆𝑙𝑙;  𝑘𝑘𝑙𝑙� + 1.96 ∙ 𝑆𝑆𝑆𝑆𝑙𝑙) for  the 
95% CI where 𝑆𝑆𝑆𝑆𝑙𝑙  is the  estimate of standard error of bootstrap mean of kinetic parameter 𝑘𝑘𝚥𝚥�  
𝑆𝑆𝑆𝑆𝑙𝑙 = ���𝑘𝑘𝑖𝑖𝑙𝑙 − 𝑘𝑘𝑙𝑙� �2𝑀𝑀
𝑖𝑖=1
/(𝑀𝑀 − 1)�1/2. 
 
 
 
2.1 Kinetic model of mTOR1 complex and its inhibition 
 
We developed a kinetic model of the catalytic cycle of the mTOR1 complex that catalyses 
phosphorylation of S6K1 and 4EBP1 kinases (Fig. 3). The model was developed in accordance 
with the framework of a two substrate random bi-bi mechanism of enzymatic reaction using an 
approximation of fast binding of substrates (ATP, S6K1 and 4EBP1) (Cornish-Bowden, 2004). In 
the catalytic cycle we considered the allosteric inhibitor of mTOR1, Rapamycin (Rap), and two 
ATP-competitive inhibitors, BEZ235 and LY294002. According to experimental data, Rapamycin 
binds with low affinity (26 μM (Banaszynski et al., 2005)) to the FRB domain of mTOR (FKBP-
rapamycin binding domain) and its binding becomes much stronger in the presence of FKBP12 
protein (FK506-binding protein 12). The high affinity of Rapamycin with FKBP12 protein (0.2 nM 
(Banaszynski et al., 2005)) leads to Rapamycin binding to mTOR1 through the formation of the 
trimeric complex FKBP12-Rapamycin-FRB with dissociation constant 12±0.8 nM (Banaszynski et 
al., 2005). In the catalytic cycle we included the mTOR1 binding reaction in the absence and 
presence of the FKBP12 with dissociation constant Kd,Rap1 and  Kd,Rap2 respectively. Considering 
these data, and other experimental data on inhibition of S6K1 and 4EBP1 phosphorylation by 
mTOR1 (Choo et al., 2008; Tao et al., 2010; Toral-Barza et al., 2005), we assumed that mTOR1 
binding to Rapamycin or Rapamycin-FKBP complexes retains its residual catalytic activity  
relating to 4EBP1 and causes its full suppression relating to S6K1 (see Fig. 3). 
 In line with the developed catalytic cycle (Fig. 3) we derived rate equations of  the 
phosphorylation of 4EBP1, V4EBP1, and S6K1, VS6K1, according to a random bi-bi mechanism 
approximation for a two substrate reaction (Cornish-Bowden, 2004; Demin and Goryanin, 2008) 
as follows:    
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𝑉𝑉4𝐸𝐸𝐸𝐸𝐸𝐸1 = 𝑘𝑘4𝐸𝐸𝐸𝐸𝐸𝐸1 ∙ 𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚1 ∙ 4𝑆𝑆𝐸𝐸𝐸𝐸1 ∙ 𝐴𝐴𝑚𝑚𝐸𝐸𝐾𝐾𝑚𝑚,4𝐸𝐸𝐸𝐸𝐸𝐸1 ⋅ 𝐾𝐾𝑚𝑚,𝐴𝐴𝐴𝐴𝐸𝐸 ∙ ∆𝑚𝑚𝐴𝐴𝑚𝑚𝑚𝑚 (1 + 𝜂𝜂4𝐸𝐸𝐸𝐸𝐸𝐸1 ⋅ 𝑚𝑚) (1) 
𝑉𝑉𝑆𝑆6𝐾𝐾1 = 𝑘𝑘𝑆𝑆6𝐾𝐾1 ∙ 𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚1 ∙ 𝑆𝑆6𝐾𝐾1 ∙ 𝐴𝐴𝑚𝑚𝐸𝐸𝐾𝐾𝑚𝑚,𝑆𝑆6𝐾𝐾1 ⋅ 𝐾𝐾𝑚𝑚,𝐴𝐴𝐴𝐴𝐸𝐸 ∙ ∆𝑚𝑚𝐴𝐴𝑚𝑚𝑚𝑚 , (2) 
where  
∆𝑚𝑚𝐴𝐴𝑚𝑚𝑚𝑚= �1 + 𝐴𝐴𝑚𝑚𝐸𝐸𝐾𝐾𝑚𝑚,𝐴𝐴𝐴𝐴𝐸𝐸 + 𝐿𝐿𝐿𝐿𝐾𝐾𝑚𝑚,𝐿𝐿𝐿𝐿 + 𝐸𝐸𝑆𝑆𝐵𝐵𝐾𝐾𝑚𝑚,𝐸𝐸𝐸𝐸𝐵𝐵� �1 + 4𝑆𝑆𝐸𝐸𝐸𝐸1𝐾𝐾𝑚𝑚,4𝐸𝐸𝐸𝐸𝐸𝐸1 + 𝑆𝑆6𝐾𝐾1𝐾𝐾𝑚𝑚,𝑆𝑆6𝐾𝐾1� (1 + 𝑚𝑚), 
 
𝑚𝑚 = 𝑚𝑚𝑅𝑅𝑅𝑅
𝐾𝐾𝑚𝑚,𝑚𝑚𝑅𝑅𝑒𝑒1 + 𝑚𝑚𝑅𝑅𝑅𝑅_𝐹𝐹𝐾𝐾𝐸𝐸𝐸𝐸𝐾𝐾𝑚𝑚,𝑚𝑚𝑅𝑅𝑒𝑒2 . 
Here Kd,i are the dissociation constants of substrates 4EBP1 and S6K1 and inhibitors Rapamycin 
(Rap), BEZ235 (BEZ), and LY294002 (LY); k4EBP1 and kS6K1 are catalytic rates. η4EBP1=     
k4EBP1,Rap/k4EBP1 is the inhibition coefficient of mTOR reaction rate for 4EBP1 phosphorylation by 
Rapamycin which is equal to the ratio of residual catalytic activity of mTOR1-Rapamycin 
complex, k4EBP1,Rap, to the catalytic activity of mTOR1, k4EBP1. Equations (1) and (2) thus describe 
the competitive kinetics of the two substrates 4EBP1 and S6K1 for enzyme mTOR1, and this 
corresponds to the two-substrate reactions catalysed by mTOR1 in cells. 
 
2.2 Kinetic model of PI3K and its inhibition by LY294002 and BEZ235 
 
A model of the catalytic cycle of PI3K catalysing the phosphorylation of PIP2 was 
developed using the same MM approximation as in the case of mTOR1 modelling (Fig. 4). In the 
catalytic cycle we considered the same ATP competitive inhibitors, LY294002 and BEZ235. 
In line with  the PI3K catalytic cycle (Fig. 4), we derived rate equations of PIP2 
phosphorylation, V4EBP1, according to a two-substrate reaction proceeding through  a random 
bi-bi mechanism (Cornish-Bowden, 2004; Demin and Goryanin, 2008):  
 
𝑉𝑉𝐸𝐸𝑃𝑃3𝐾𝐾 = 𝑘𝑘𝐸𝐸𝑃𝑃3𝐾𝐾 ∙ 𝐸𝐸𝑃𝑃3𝐾𝐾 ∙ 𝐸𝐸𝑃𝑃𝐸𝐸2 ∙ 𝐴𝐴𝑚𝑚𝐸𝐸𝐾𝐾𝑚𝑚,𝐸𝐸𝑃𝑃𝐸𝐸2 ⋅ 𝐾𝐾𝑚𝑚,𝐴𝐴𝐴𝐴𝐸𝐸 ∙ ∆𝐸𝐸𝑃𝑃3𝐾𝐾  (3) 
where 
 
∆𝐸𝐸𝑃𝑃3𝐾𝐾= �1 + 𝐸𝐸𝑃𝑃𝐸𝐸2𝐾𝐾𝑚𝑚,𝐸𝐸𝑃𝑃𝐸𝐸2��1 + 𝐴𝐴𝑚𝑚𝐸𝐸𝐾𝐾𝑚𝑚,𝐴𝐴𝐴𝐴𝐸𝐸 + 𝐿𝐿𝐿𝐿𝐾𝐾𝑚𝑚,𝐿𝐿𝐿𝐿 + 𝐸𝐸𝑆𝑆𝐵𝐵𝐾𝐾𝑚𝑚,𝐸𝐸𝐸𝐸𝐵𝐵� 
 
 
2.3 Kinetic model of PTEN 
 
To model PTEN kinetics we used experimental data on PTEN activity, measured in 
unilamellar mixed phosphatidylcholine vesicles containing lipid substrate PIP3 (McConnachie et 
al., 2003). In this experiment bulk concentration of substrate PIP3 was varied at different fixed 
surface concentrations of PIP3, XPIP3 (mole fraction), in the vesicles. As a result,  the dependence 
of PTEN activity with respect to hydrolysing of PIP3 on bulk concentration of PIP3 at the different 
XPIP3 was obtained. To model these kinetic data, we used a MM rate equation: 
𝑉𝑉𝐸𝐸𝐴𝐴𝐸𝐸𝑃𝑃 = 𝑘𝑘𝐸𝐸𝐴𝐴𝐸𝐸𝑃𝑃 ∙ 𝐸𝐸𝑚𝑚𝑆𝑆𝑃𝑃 ∙ 𝐸𝐸𝑃𝑃𝐸𝐸3𝐾𝐾𝐸𝐸𝑃𝑃𝐸𝐸3 + 𝐸𝐸𝑃𝑃𝐸𝐸3𝑠𝑠  (4) 
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where  kPTEN and  KPIP3 are catalytic and Michaelis constants respectively and PIP3s= XPIP3PIP3. 
 
3. Results 
 
3.1. mTOR1 kinetic model parameterisation and validation through drug action  
 
To determine the kinetic parameters of Eqs. (1) and (2) we used in vitro experimental data 
on the phosphorylation of 4EBP1(Thr46) and S6K1(Thr389) by mTOR kinase (Tao et al., 2010; 
Toral-Barza et al., 2005). Reproducing the experimental conditions of these in vitro experiments 
in our in silico model, we carried out the joint fitting of a set of experimental data including the 
dependencies of reaction rate V4EBP1 (Eq. (1)) on 4EBP1 concentration and also on ATP 
concentration at different concentrations of Rapamycin (Tao et al., 2010). Experimental data 
and the results of fitting are shown in Fig. 5A and 5B. A set of obtained kinetic parameters along 
with the results of the bootstrap procedure (see Method) are given in Table 1. As a result of the 
bootstrap procedure, we obtained bootstrap samples of kinetic parameters and gave the 
medians and the 95% percentile confidence interval for each parameters. The number of 
bootstrap samples in our calculations was 200 to ensure stable values of the medians and CVs. 
We also calculated the means and the standard normal confidence interval (see Methods) for 
the bootstrap samples and gave them in Table S1 in Supplement 6. Comparison of the means, 
medians, and CIs of the kinetics parameters obtained by two methods revealed similar results.  
According to modelling, mTOR kinase retains a fraction of its activity following Rapamycin 
inhibition due to its residual catalytic activity. Results of the fitting showed that mTOR1 retains 
40% of catalytic activity at Rapamycin binding: the catalytic rate k4EBP1 is changed by the factor 
η4EBP1 =0.42 μM CI(10-3; 0.5) in the presence of Rapamycin (see the residual level of kinase 
activity in Fig. 5C and Table 1). The dissociation constant Kd,Rap2=6 nM CI(3.1; 6.9); obtained 
through fitting is close to the experimental value 12±4.2 nM and for the trimeric complex 
FKBP12-Rapamycin-FRB measured  by surface plasmon resonance (SPR) methods (Banaszynski 
et al., 2005). The value of the dissociation constant of ATP, Kd,ATP =8.4 µM CI(6.2; 8.9) obtained 
in our calculation, is substantially smaller than the value of the Michaelis constant  74 μM 
obtained in (Tao et al., 2010) based on the fitting of experimental data by the Michaelis-Menten 
equation (Fig. 5B). This discrepancy may be due to the facts that first we used a wider range of 
experimental data in the fitting procedure than used in (Tao et al., 2010) and second we defined 
the dissociation constant of ATP, Kd,ATP, in our model rather than the apparent Michaelis 
constant obtained in (Tao et al., 2010). 
 To validate the model with the obtained set of kinetic parameters we calculated the 
concentration dependence of mTOR1 activity (Eq. (1)) on Rapamycin concentration and found 
satisfactory agreement with the experimental dose dependence (Fig. 5C, line 1). We also 
calculated the dose dependence of mTOR1 activity on the concentration of BEZ235 (Fig. 5C, line 
2). Comparison of the two dose dependencies for Rapamycin and BEZ235 shows that Rapamycin 
inhibits 60% of mTOR1 catalytic activity while BEZ235 suppresses activity totally (Fig. 5C). In this 
calculation, we determined the dissociation constant of BEZ235, Kd,BEZ, via the fitting of this 
single parameter of the model (Eq. (1)) against the experimental dose dependence on reaction 
rate inhibition of truncated mTOR kinase (Tao et al., 2010). The obtained dissociation constant, 
Kd,BEZ=0.56 nM CI(0.48; 0.57), is close to the Michaelis constants Km=2.5 nM and 1.7 nM obtained 
based on the Michaelis-Menten equation fitting to radiometric and FRET assay data respectively 
(Tao et al., 2010) (Table 1). The obtained dissociation constant Kd,BEZ allows calculation of the 
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IC50 value at the ATP concentration used in the experimental assay according to the following 
equation 
 
𝑃𝑃𝐼𝐼50 = 𝐾𝐾𝑚𝑚,𝐸𝐸𝐸𝐸𝐵𝐵 �1 + 𝐴𝐴𝑚𝑚𝐸𝐸𝐾𝐾𝑚𝑚,𝐴𝐴𝐴𝐴𝐸𝐸�. (5) 
Eq. (5)  follows from Eq. (1) and a definition of the IC50 value as the inhibitor concentration 
corresponding to a 50% inhibition of reaction rate V4EBP1 (derivation of Eq. (5) is given in 
Supplement 1). At concentration ATP=100 μM Eq. (5) gives IC50 = 8 μM that is close to the 
experimental value of IC50 = 10 nM obtained from the experimental dose dependence (Tao et 
al., 2010) (see experimental data in Fig. 5C). Accordingly, Eq. (5) parameterised with an ATP-
competitive mTOR1 inhibitor allows calculation of the IC50 values for BEZ235 at different ATP 
concentrations in an experimental assay and estimation of BEZ235 IC50 for different cells using 
a known ATP concentration. 
  In contrast to IC50 dependence (Eq. (5)) for the ATP-competitive inhibitor, the IC50 for the 
allosteric inhibitor Rapamycin does not depend on ATP concentration and according to Eq. (1) 
is equal to its dissociation constant: 
 
𝑃𝑃𝐼𝐼50 = 𝐾𝐾𝑚𝑚,𝑚𝑚𝑅𝑅𝑒𝑒 , (6) 
where 𝐾𝐾𝑚𝑚,𝑚𝑚𝑅𝑅𝑒𝑒 is either dissociation constant 𝐾𝐾𝑚𝑚,𝑚𝑚𝑅𝑅𝑒𝑒1 or 𝐾𝐾𝑚𝑚,𝑚𝑚𝑅𝑅𝑒𝑒2  depending the absence or 
presence of the FKBP12 protein in assays. This exact equality follows from the equation of 
reaction rate 𝑉𝑉4𝐸𝐸𝐸𝐸𝐸𝐸1 Eq (1)  (see derivation in Supplement 2). Comparison of the experimental 
IC50=9.6 nM (+FKBP12) and IC50>1 µM (no FKBP12) with the theoretical values 𝐾𝐾𝑚𝑚,𝑚𝑚𝑅𝑅𝑒𝑒2 =6 nM 
CI(3.1; 6.9) and 𝐾𝐾𝑚𝑚,𝑚𝑚𝑅𝑅𝑒𝑒1  =1.7 μM CI(1.3; 1.8) confirms this relationship. 
To determine the kinetic parameters of mTOR1 related to the phosphorylation reaction 
of S6K1 kinase as described by Eq. (2) we used in vitro experimental data on the dependence of 
the reaction rate of S6K1(T389) phosphorylation on ATP concentration at different 
concentrations of LY294002 inhibitor (Toral-Barza et al., 2005). Given that LY294002 is a 
nonspecific inhibitor of PI3K (Vlahos et al., 1994), and considering the high homology in catalytic 
sites between PI3K and TOR kinases (Yang et al., 2013), we assumed that LY294002 inhibits 
mTOR1 by a similar mechanism to PI3K (see mTOR1 catalytic cycle in Fig. 3). Results of the fitting 
are shown in Fig. 6A and kinetic parameters obtained are given in Table 1. To demonstrate 
clearly that LY294002 is an ATP-competitive inhibitor of mTOR kinase, we also presented 
theoretical and experimental kinetic data in the Lineweaver-Burk plot in Supplement 3.  
To obtain the dissociation constants of Rapamycin binding to mTOR1, Kd,Rap1 and Kd,Rap2, 
we used the experimental dose dependence of the inhibition of S6K1(Thr389) phosphorylation 
reaction rate by Rapamycin (Toral-Barza et al., 2005). Given the derived kinetic parameters 
(Table 1) and concentrations of species in the experimental assay (Toral-Barza et al., 2005) we 
defined Kd,Rap1=1.7 μM CI(1.3; 1.8); and Kd,Rap2=1.6 nM CI(1.2; 1.7) in the absence and presence 
of FKBP12 respectively (Fig. 6B). The obtained values in the presence of FKBP12 are in 
agreement with nanomole values of dissociation constant: 0.35 nM and 12±0.8 nM obtained by 
fluorescence polarization assay (FPA) and SPR methods respectively (Banaszynski et al., 2005). 
The experimental dissociation constant in the absence of FKBP12 is 490±39 nM and 26±0.8 μM 
obtained by FPA and SPR methods respectively (Banaszynski et al., 2005). Note that the values 
of dissociation constants of Rapamycin and mTOR kinase domain obtained in the model and 
those from experimental methods are close to the experimental values of IC50=2 nM in the 
presence of FKBP12 and IC50> 1 μM in the absence of FKBP12 in the experimental assay of 
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S6K1(Thr389) phosphorylation (Toral-Barza et al., 2005), and these values conform to the 
relationship between Kd and IC50 values given by Eq. (6) for an allosteric inhibitor. 
To validate the mTOR1 model (Eq. (2)) with the parameter set (Table 1) we calculated the 
dose dependence of inhibition of S6K1(Thr389) phosphorylation by LY294002 (Fig. 6C), and 
compared the results with experimental data (Toral-Barza et al., 2005). In a similar manner to 
Eq. (5) the dependence of IC50 for LY294002 on ATP concentration is given by the equation  
 
𝑃𝑃𝐼𝐼50 = 𝐾𝐾𝑚𝑚,𝐿𝐿𝐿𝐿 �1 + 𝐴𝐴𝑚𝑚𝐸𝐸𝐾𝐾𝑚𝑚,𝐴𝐴𝐴𝐴𝐸𝐸�, (7) 
 
which allows us to obtain the LY294002 IC50 value at the ATP concentration used in the 
experimental assay. At ATP concentration of 100 μM (Toral-Barza et al., 2005), Eq. (5) gives 
IC50=1.5 μM that corresponds to the experimental IC50 value obtained in this experiment (see 
experimental data in Fig. 6C). Accordingly, the satisfactory parameterisation of Eq. (7) for 
LY294002 may be used to calculate the LY294002 IC50 values at different concentrations of ATP 
in in vitro assays.   
We applied Eq. (7) to calculate the dose dependence of mTOR1 for LY294002 at 2 μM ATP 
and compared the obtained result with that calculated at 100 μM ATP (lines 1 and 2 in Fig. 6C). 
As LY294002 is an ATP-competitive inhibitor of mTOR1, the IC50 decreases when ATP decreases 
(IC50=0.15 μM at 2 μM ATP).  Modelling showed that LY294002 becomes a stronger inhibitor of 
mTOR1 at low ATP concentrations in the range 1 μM - 10 μM, which corresponds to ATP 
concentration in mammalian cells (McLaughlin et al., 2002). Note, according to Eq. (6), the 
inhibition activity of the allosteric inhibitor Rapamycin does not depend on ATP concentration. 
To investigate synergistic effects of the combination of the allosteric inhibitor Rapamycin with 
the ATP-competitive inhibitor LY294002 we calculated the dose dependence of mTOR1 
inhibition on LY294002 concentration at 10 nM Rapamycin and 100 μM ATP (line 3 in Fig. 6C). 
The calculation revealed an additive effect of the two inhibitors and an increase of the LY294002 
IC50 value from 1.5 μM to 30 μM when in combination with Rapamycin. Thus results do not 
indicate any synergistic effects of Rapamycin and LY294002 in combination. 
 
3.2 PI3K kinetic model parameterisation and validation through drug action 
 
The kinetic parameters of PI3K were derived by fitting of reaction rate VPI3K (Eq. (3)) against 
in vitro experimental data on the phosphorylation of PIP2 (Huang et al., 2011; Vlahos et al., 
1994). Figs. 7A, B, and C show the results of fitting of the dependencies of the reaction rates on 
ATP and PIP2 concentrations in the absence and presence of LY294002 inhibitor. The form of 
the fitted Lineweaver-Burk plot confirms that LY294002 is an ATP-competitive inhibitor of PI3K 
(Fig. 7C). The obtained kinetic parameters of the kinase and dissociation constant of LY294002 
are provided in Table 2.  
To estimate the dissociation constant of BEZ235 we applied the PI3K model to describe 
the dose dependence of ADP release on the inhibitor concentration for PI3Kα enzyme (Maira 
et al., 2008).  To reproduce experimental data (Maira et al., 2008), we modelled ADP production 
by an ordinary differential equation with the initial conditions corresponding to the 
experimental assay:  
𝑑𝑑𝐴𝐴𝑑𝑑𝐸𝐸
𝑑𝑑𝑑𝑑
= 𝑉𝑉𝐸𝐸𝑃𝑃3𝐾𝐾 , (8) 
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where reaction rate VPI3K is defined by Eq. (3). The dissociation constant obtained as a result of 
best fitting of experimental dose dependence of ADP production on BEZ235 concentration (see 
Fig. 7D, line 1) is provided in Table 2 with experimental data on Ki and IC50 values for BEZ235 
available from literature. We also used similar experimental data (Maira et al., 2008) to calculate 
the dose dependence for the LY294002 inhibitor. Comparison of the dose dependencies for 
BEZ235 and LY294002 is shown in Fig. 7D by lines 1 and 2 respectively. The dissociation constant 
Kd,LY=0.1±0.02  µM obtained for PI3Kα isoform as a result of the best fitting of experimental 
dose dependence is less than Kd,LY=0.7±0.1 µM obtained above for bovine brain PI3K isolated in 
experimental work (Vlahos et al., 1994). The obtained dissociation constant Kd,LY=0.1±0.02 µM 
is close to the dissociation constant Kd,LY =0.21±0.04 µM for the PI3Kγ isoform measured by the 
intrinsic tryptophan fluorescence method (Walker et al., 2000).  
To validate the calibrated model of PI3K (Eqs. (3) and (8)) we used the model to describe 
the experimental dependence of the IC50 value for BEZ235 and LY294002 on ATP concentration 
measured for dose dependence of ADP production for a PI3Kγ enzyme assay (Maira et al., 2008). 
The theoretical ATP dependence of the IC50 values for BEZ235 and LY294002 was obtained based 
on the analytical solution of Eq. (8). As a solution of Eq. (8) cannot be written explicitly we  
expressed the dependence of the IC50  value on the initial ATP concentration 𝐴𝐴𝑚𝑚𝐸𝐸0 in the form  
 
𝑃𝑃𝐼𝐼50 = 𝐾𝐾𝑚𝑚,𝑖𝑖 � 𝑙𝑙𝑙𝑙�𝐴𝐴𝐴𝐴𝐴𝐴𝐼𝐼0𝐴𝐴𝐴𝐴𝐴𝐴0 �−𝐸𝐸𝑡𝑡𝑚𝑚 
2𝑙𝑙𝑙𝑙�
1
2
�1+
𝐴𝐴𝐴𝐴𝐴𝐴𝐼𝐼0
𝐴𝐴𝐴𝐴𝐴𝐴0
��
− 1�,      (9) 
where 
𝐸𝐸 = 𝑘𝑘𝐸𝐸𝑃𝑃3𝐾𝐾 ∙ 𝐸𝐸𝑃𝑃3𝐾𝐾 ∙ 𝐸𝐸𝑃𝑃𝐸𝐸2
𝐾𝐾𝑚𝑚,𝐸𝐸𝑃𝑃𝐸𝐸2 ⋅ 𝐾𝐾𝑚𝑚,𝐴𝐴𝐴𝐴𝐸𝐸 �1 + 𝐸𝐸𝑃𝑃𝐸𝐸2𝐾𝐾𝑚𝑚,𝐸𝐸𝑃𝑃𝐸𝐸2�−1.                                         
 
Here 𝐴𝐴𝑚𝑚𝐸𝐸𝑃𝑃0 = 𝐴𝐴𝑚𝑚𝐸𝐸(𝑑𝑑𝑚𝑚, 𝑃𝑃 = 0) is the final concentration of ATP at the reaction terminal time 𝑑𝑑𝑚𝑚 
in the absence of inhibitors which can be defined from Eq. (8). The detailed derivation of Eq. (9) 
is given in Supplement 4. The obtained Eq. (9) allows calculating dependence of the 𝑃𝑃𝐼𝐼50 value 
on the initial concentration 𝐴𝐴𝑚𝑚𝐸𝐸0 based on the solution of Eq. (8) 𝐴𝐴𝑚𝑚𝐸𝐸(𝑑𝑑𝑚𝑚, 𝑃𝑃 = 0) = 𝐴𝐴𝑚𝑚𝐸𝐸0 −
𝐴𝐴𝑑𝑑𝐸𝐸(𝑑𝑑𝑚𝑚, 𝑃𝑃 = 0) in the absence of inhibitors. Note using of this equation to does not require 
calculation of dose dependence for the inhibitor at the different concentrations of ATP and 
numerical estimation of   𝑃𝑃𝐼𝐼50 values. The dependencies of the 𝑃𝑃𝐼𝐼50 value for BEZ235 and 
LY294002 on 𝐴𝐴𝑚𝑚𝐸𝐸0 concentration was calculated based on Eq. (9) with kinetic parameters 
obtained in the fitting procedure (Table 2) and the initial concentrations of the substrates 
corresponding to the experimental conditions in the work (Maira et al., 2008). Dissociation 
constants for BEZ235 and LY294002 in these calculations were 𝐾𝐾𝑚𝑚,𝐸𝐸𝐸𝐸𝐵𝐵 = 2 nM and 𝐾𝐾𝑑𝑑,𝐿𝐿𝐿𝐿 = 0.7 µM 
which lie within the obtained CI of these parameters (Table 2). 
In Fig. 8A, we compared the obtained theoretical dependencies with experimental data 
(Maira et al., 2008). The linear dependence of the IC50 values on 𝐴𝐴𝑚𝑚𝐸𝐸0 concentration obtained 
in the model corresponds to the ATP-competitive mechanism for BEZ235 and LY294002 
inhibitors (Fig. 8A and 8B respectively) and satisfactorily describes the observed experimental 
dependencies of the IC50 values for these inhibitors (Maira et al., 2008).  To investigate the value 
where the line intercepts the 𝑃𝑃𝐼𝐼50-axis, we plot the linear dependence of the IC50 values on ATP 
concentration (dotted lines in Figs. 8A and 8B) obtained based on the dose dependence of the 
reaction rate 𝑉𝑉𝐸𝐸𝑃𝑃3𝐾𝐾 on the inhibitor concentration (Eqs. (5) and (7)).  Exact coincidence between 
two lines shows equivalence of the 𝑃𝑃𝐼𝐼50measurement in both in vitro assays at the specific 
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experimental conditions. Therefore, the intercept of the regression line may serve as an 
estimate of dissociation coefficients of ATP-competetive inhibitors. For the LY294002 and 
BEZ235 IC50s, we got estimates for  𝐾𝐾𝑚𝑚,𝐸𝐸𝐸𝐸𝐵𝐵 = 2 nM and 𝐾𝐾𝑑𝑑,𝐿𝐿𝐿𝐿 = 0.7 µM respectively that 
satisfactorily agrees with the fitted values of these dissociation constants  (Table 2). Thus 
experimental data IC50 on ATP concentration for ATP-competitive inhibitors can be used to 
estimate dissociation constant of the inhibitors. 
 
 
3.3 PTEN kinetic model parameterisation  
 
Fig. 9 (lines) shows the fitting of the reaction rate VPTEN (Eq. (4)) depending on PIP3 
concentration at four surface concentrations of PIP3, XPIP3 (mole fraction), against experimental 
data (McConnachie et al., 2003). As a result of fitting, a low value of the Michaelis constant was 
obtained, KPIP3=29  nM (20; 31) nM. Plotting theoretical and experimental data in the reciprocal 
axes, 1/PIP3 and 1/VPTEN, showed that the rate equation in the form (Eq. (8)) describes 
satisfactorily the kinetic behaviour of VPTEN at different XPIP3. Moreover the straight lines 
corresponding to different XPIP3 intersect the 1/VPTEN axis at the same point, which means that 
maximum rate of PTEN is independent of XPIP3, and the reaction rate VPTEN  depends on the 
concentration of PIP3 in the membrane (XPIP3⋅ PIP3) according to Eq. (4). 
 
Discussion 
 
The results of our kinetic modelling of PI3K, mTOR1 kinases and PTEN phosphatase 
showed that in vitro kinetics of these purified proteins can be described satisfactorily with 
Michaelis-Menten approximation, i.e. with a fast substrate binding approximation. The 
obtained kinetic parameters of these proteins are partly in agreement with those obtained 
previously by the fitting of MM equations against separate kinetic curves (Maira et al., 2008; 
Tao et al., 2010; Toral-Barza et al., 2005). In line with the schematic in Fig. 2 we enhanced the 
estimation of a number of kinetic parameters of PI3K and mTOR1 kinases through the 
application of two-substrate reaction rate equations calibrated against experimental data 
describing kinetics in different experimental conditions. This calibration approach allowed us to 
estimate dissociation constants of the substrates instead of apparent Michaelis constants that 
depend on experimental assay conditions such as the second substrate concentration in two-
substrate reactions. The developed models were then applied to describe allosteric inhibition 
of mTOR kinase by Rapamycin and ATP-competitive inhibition of PI3K and mTOR kinases by 
LY294002 and BEZ235.  
Modelling of the mTOR kinase showed high selectivity of allosteric inhibitor Rapamycin to 
mTOR1 substrates: Rapamycin differentially regulates mTOR1 activity relating to its substrates 
S6K1 and 4EBP1. In the model, Rapamycin changes the catalytic rate of 4EBP1 phosphorylation 
k4EBP1 by a factor of η4EBP1=0.4 (Fig. 5C and Table 1). Analysis of the kinetic data and dose 
dependence showed that mTOR1 retains 40% of catalytic activity without a change in 
dissociation constant to the substrate, Kd,4EBP1 (Fig. 5). In contrast, Rapamycin both alone and in 
a complex with FKBP12 inhibits completely the catalytic activity of mTOR1 relating to S6K1 
phosphorylation (ηS6K1=0). In agreement with experimental data, the modelling showed that 
Rapamycin completely inhibits S6K1 phosphorylation at a Rapamycin concentration greater 
than 0.1 µM and 100 µM in the presence and absence of FKBP12 respectively (Shor et al., 2008)  
(Fig. 6D).  
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Experimental investigations into the crystal structure of a truncated mTOR kinase (Yang 
et al., 2013) suggest that the binding of Rapamycin-FKBP12 complex near the mTOR substrate-
binding site inhibits kinase activity due to restricting the accessibility of the substrates to the 
recessed catalytic cleft. As per the schematic in Fig. 2, we can integrate this knowledge into the 
model. According to our modelling, the Rapamycin-FKBP12 complex does not compete with 
mTOR1 substrates and it binds to mTOR1 jointly with either 4EBP1 or S6K1 kinases and forms 
triple complexes in the form Rapamycin-FKBP1-mTOR-Substrate as depicted in the scheme of 
the mTOR catalytic cycle (Fig. 3). In the model, Rapamycin decreases the mTOR1 catalytic rate 
relating to 4EBP1 and S6K1 without impacting mTOR1 affinity to substrates (Table 1). This 
decrease in catalytic rate may result from the observation that the Rapamycin-FKBP12 complex 
perturbs the positioning of the substrate at the catalytic site but does not influence significantly 
substrate binding. We suggest that the observed differences in catalytic rate is responsible for 
Rapamycin selectivity to mTOR1 substrates and this property might be due to steric effect 
stemming from the different sizes of S6K1 and 4EBP1 proteins: 60 KDa and 18 KDa respectively. 
Thus the active site restriction mechanism proposed in (Yang et al., 2013) corresponds to the 
negative regulation mechanism of catalytic rate in our model.  
 Yang et al. (Yang et al., 2013) propose a biparticle substrate-recruitment mechanism for 
S6K1 binding to the mTOR active site, according to which the FRB provides a secondary binding 
site for the substrate near the entrance to the catalytic cleft. They suggest that this Rapamycin-
binding site participates in substrate binding with the recessed active site of mTOR. In our 
kinetic modelling, Rapamycin both alone and in a complex with FKBP12 does not change the 
dissociation constants of either substrate 4EBP1 or S6K1, and only influences the catalytic rate 
of the enzyme. Accordingly, we suggest that either: 1) our analysis of kinetic data is not sensitive 
to the biparticle substrate-recruitment mechanism suggested in (Yang et al., 2013); or 2) the 
Rapamycin-binding site interacts with other parts of mTOR, which changes the catalytic rate of 
the enzyme and defines an allosteric inhibition mechanism (Choo et al., 2008; Yang et al., 2013). 
An allosteric mechanism of mTOR1 inhibition by Rapamycin is supported by modelling kinetic 
data on the dependence of 4EBP1 phosphorylation reaction rate on ATP concentration at 
different concentrations of Rapamycin (Tao et al., 2010), which shows inhibition of the catalytic 
rate  without changing substrate affinity (Fig. 5A).  
In the model, the FKPB12 protein enhances affinity of Rapamycin to the FRB domain of 
mTOR and does not influence substrate affinity. Note our modelling showed that the 
dissociation constant of complex Rapamycin-FKBP1 Kd,Rap2 differs for the substrates 4EBP1 and 
S6K1 (7±1.1 nM and 1.5±0.5 nM respectively) and these values correlate with their experimental 
IC50 values (9.6 nM and 2 nM respectively, Table 1). This difference may indicate steric 
interaction between Rapamycin-FKBP12 complex and the substrates in the model.  A high 
affinity of Rapamycin-FKBP12 complex to the mTOR1-S6K1 complex contributes to higher 
inhibition of S6K1 in comparison with 4EBP1. Note, the calculation revealed high selectivity of 
mTOR1 to its substrates 4EBP1 and S6K1 (10.3±2 μM and 0.4±0.2 μM respectively). Additionally, 
mTOR1 was reported to show high selectivity to S6K isomers, S6K1 and S6K2, expressing 
differently in specific cells (So et al., 2016). 
To juxtapose in vitro kinetic data for purified enzymes and in vivo data for cell culture we 
compared modelling results and experimental data on inhibition of cancer cell population by 
Rapamycin (Brachmann et al., 2009). Residual activity of mTOR1 (40%) relating to 4EBP1 
phosphorylation obtained in the modelling correlates with survival dose dependence for a set 
of breast cancer cell lines treated by Everolimus (a derivative of Rapamycin) for (residual activity 
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is ∼50%) (Brachmann et al., 2009). This fact suggests that inhibition of 4EBP1 exerts primary 
effect on cancer cell proliferation in comparison with S6K1 inactivation (So et al., 2016). 
While a Michaelis-Menten approximation may satisfactorily describe the main features of 
mTOR kinetics, many kinetic properties lie out with the descriptive power of the MM approach. 
For example, whilst modulation of the mTOR1 activity by Rapamycin is described satisfactorily 
based on the kinetic properties of mTOR kinase, the inhibition of mTORC2 complex is not 
incompatible with the MM approximation: Rapamycin does not inhibit mTOR2 in the nanomolar 
concentration range (Yang et al., 2013) and a reduction in mTOR2 activity is only observed upon 
prolonged incubation with nanomolar rapamycin (Sarbassov et al., 2006). The mechanisms 
underlying this difference are presumably due to the different structural components of mTOR1 
and mTOR2 complexes, including the fact that FKBP12-Rapamycin binds with a de novo 
assembled mTOR2 complex that hinders binding of Rictor components to the mTOR2 complex 
(Shor et al., 2008; Yang et al., 2013).  
Our model does explain the Rapamycin selectivity to mTOR1 substrates S6K1 and 4EBP1 
at the enzymatic level, but it is problematic to translate this on-target mechanism to in vivo 
data: Rapamycin was reported to inhibit S6K1 kinase in all cell lines that were tested, while the 
phosphorylation inhibition of 4EBP1 depends on cell type (Choo et al., 2008). Moreover in many 
cell types recovery from the initial inhibition of 4EBP1 was observed within 6 hours and was 
followed by its hyper-phosphorylation, which causes a recovery in cap-dependent translation 
despite continued S6K1 inhibition as a result of Rapamycin treatment (Choo et al., 2008). A 
further anomaly of mTOR kinase behaviour observed in vivo is that phospho-sites 
4EBP1(T37/46), which are direct targets of mTOR kinases in vitro, are not Rapamycin sensitive 
in vivo, yet T389 on S6K1 is Rapamycin sensitive in vitro and in vivo (Choo et al., 2008).   
The developed model of mTOR kinase was applied to describe the action of ATP-
competitive inhibitors LY294002 and BEZ235. The dissociation constants Kd obtained in the 
calculation were significantly smaller than the IC50 values observed in in vitro experiments (Tao 
et al., 2010). To explain this difference, we used the dependence of the IC50 value for ATP-
competitive inhibitor on ATP concentration, derived in the MM approximation. This 
dependence of the IC50 values for BEZ235 and LY294002 (Eqs. (5) and (7) respectively) describes 
well the observed difference between the Kd and IC50 values. The obtained dependence can be 
used to calculate the IC50 values for these inhibitors for different experimental assays and for 
the estimation of IC50 in in vitro experiments in cells with different ATP levels. These relations 
can be also used in the analysis of variation in the IC50 values for LY294002 and BEZ235 inhibitors 
in cancer lines characterizing by different ATP levels (Moreno-Sánchez et al., 2014; Zhou et al., 
2012). 
Note that according to the model of mTOR1 kinase (Eqs. (1) and (2)) and general 
properties of MM approximation (Brandt et al., 1987; Yung-Chi and Prusoff, 1973) the IC50 value 
for allosteric inhibitor Rapamycin does not depend on ATP concentration and its IC50 is equal to 
the dissociation constant of Rapamycin Kd,Rap in relation to Eq. (6). This result is in agreement 
with experimental IC50 values (2 nM and 7 nM for S6K1 and 4EBP1 respectively) which are close 
to theoretical dissociation constants Kd,Rap =1.5±0.5  nM and 7±1.1  nM respectively (Table 1). A 
comparison of dose dependencies for treatment of different cancer cell lines by rapalog, 
RAD001, showed that the lethal dose, LD50 ≅ 10 nM (Santiskulvong et al., 2011), is almost 
independent of cell lines sensitive to RAD001 and satisfactorily correlates with the dissociation 
constant and IC50 values obtained in the modelling.  
To investigate the joint effect of allosteric and ATP-competitive inhibitors on the mTOR 
kinase activity we calculated mTOR inhibition by the combination of Rapamycin and LY294002. 
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The result showed an additive and not a synergistic effect of this combination. Experimental 
data showed that a combination of Rapamycin and LY294002 suppresses AKT phosphorylation 
but without significant effect on treatment efficacy (Werzowa et al., 2009).  
PTEN kinetics were modelled based on experimental data on PTEN activity measured in 
phosphatidylcholine vesicles at different molar fractions of PIP3 (McConnachie et al., 2003). We 
modelled PIP3 phosphatase activity of PTEN by a Michaelis-Menten equation that considered 
PIP3 fraction in mixed lipid vesicles. Our model is simpler than the three-parameter model used 
in (McConnachie et al., 2003) to describe the hopping/scooting mechanism of PTEN catalysis 
(see Michaelis-Menten-like equation in Table 3). In this model, the maximum reaction rate 
depends on the surface fraction of PIP3 in the vesicle membrane, and the rate equation takes 
into account non-specific binding of PTEN to the membrane surface with low affinity, KS =84 
mM (McConnachie et al., 2003). In our model we showed that experimental PTEN kinetics might 
be satisfactory described in Michaelis-Menten approximation where the maximum reaction 
rate does not depend on molar fraction of PIP3 in the membrane and that the reaction occurs 
through the formation of Michaelis-Menten enzyme-substrate complex without non-specific 
binding of PTEN to the membrane. Our model gave a low Michaelis constant KPIP3=43 nM that 
suggests that PTEN is highly sensitive to low concentrations of PIP3 lipids produced in the 
plasma membrane during PI3K activation (Maehama et al., 2001).  
Here, our modelling and obtained results show that integrated analysis of experimental 
data on enzymatic kinetics, enzyme activity following drug action, and enzyme molecular 
structure gives mutually complementary information on regulation mechanisms of catalysis and 
mechanisms of inhibitor action in various experimental conditions. Our framework provides an 
approach to integrate protein and drug data into a unified, validated kinetic model that may be 
used to predict drug efficacy in a range of cellular conditions.  
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Figure legends  
 
Fig. 1. Scheme of PI3K/PTEN/AKT/mTOR1 pathway activated by growth factor (GF) and inhibited 
by allosteric inhibitor, Rapamycin, and ATP-competitive inhibitors BEZ235 and LY294002. 
 
Fig. 2. Systems biology approach to kinetic model design, discrimination, and calibration: 
incorporation and fitting of in vitro data obtained under different experimental conditions. 
Application of the model to the prediction of IC50 values for drugs in different in vitro and in vivo 
conditions. 
 
Fig. 3. Catalytic cycle of mTOR1 complex catalysing the reactions of S6K1 and 4EBP1 
phosphorylation in the presence of ATP-competitive inhibitors (Inh) either BEZ235 or LY294002 
and allosteric inhibitor Rapamycin (Rap).  
 
Fig. 4. Catalytic cycle of PI3K in the presence of ATP-competitive inhibitors, BEZ235 and 
LY294002.  
 
Fig. 5. (A): Reaction rate of 4EBP1(Thr46) phosphorylation catalysed by mTOR kinase  depending 
on ATP concentration at different concentrations of Rapamycin. Lines - theoretical results: line 
1 - 0 nM, line 2 – 8 nM, line 3 – 20 nM, line 4 – 128 nM. Points - experimental data: 200 nM 
4EBP1, 3 nM truncated mammalian mTOR kinase, 200 nM FKBP12 protein in TR-FRET assay (Tao 
et al., 2010). (B): Reaction rate of 4EBP1(Thr46) phosphorylation catalysed by mTOR kinase 
depending on 4EBP1 concentration. Line - theoretical result. Points - experimental data: 300 μM 
ATP, 6.7 nM truncated mammalian mTOR kinase in radiometric filtration assay (Tao et al., 2010). 
(C): Dose dependence of mTOR1 reaction rate inhibition by Rapamycin (line 1) and BEZ235 (line 
2). Lines – theoretical results. Points - experimental data: 40 μM 4EBP1, 20 nM mammalian 
mTOR1, and 100 μM ATP in radiometric filtration assay (Tao et al., 2010).      
 
Fig. 6.   (A): Dependence of mTOR1 reaction rate of S6K1(Thr389) phosphorylation on ATP 
concentration at different concentrations of LY294002 inhibitor. Lines - theoretical results:  line 
1 - 0 μM, line 2 - 0.8 μM, line 3 - 1.6 μM, and line 4 - 3.2 μM LY294002. Points - experimental 
data:  1.25 μM S6K1, ATP 100 μM, 6 nM FLAG-TOR in the assay (Toral-Barza et al., 2005).  (B): 
Dose dependence of mTOR kinase reaction rate of S6K1(Thr389) phosphorylation on  Rapamycin 
concentration in the presence (line 1) and absence of FKBP12  (line 2). Lines -theoretical results. 
Points - experimental data: circles and triangles (Toral-Barza et al., 2005), squares (Shor et al., 
2008). Experimental conditions: 1.25 μM S6K1, 6 nM FLAG-TOR, and 100 μM ATP in the assay. 
(C): Dose dependence of inhibition of FLAG-TOR(3.5) reaction rate of S6K1(Thr389) 
phosphorylation by LY294002. Lines 1 and 2 - theoretical calculation at 100 μM and 2 μM ATP, 
respectively. Points - experimental data:  1.25 μM S6K1, 100 μM ATP, 6 nM FLAG-TOR(3.5) in the 
assay (Toral-Barza et al., 2005).  Line 3 - computational dose dependence of inhibition of mTOR 
kinase by combination of LY294002 and  Rapamycin (10 nM) at 100 μM ATP. 
 
Fig. 7.  (A): The dependence of PI3K reaction rate on ATP concentration.  Line – theoretical result. 
Points - experimental data:  2 μM PIP2 in the assay (Huang et al., 2011). (B): The dose 
dependence of PI3K reaction rate on PIP2 concentration. Line – theoretical result. Points - 
experimental data:  2 mM ATP in the assay (Huang et al., 2011). (C): Lineweaver-Burk plot of 
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PI3K reaction rate for different LY294002 concentrations: line 1 - 0 μM, line 2 - 1 μM, line 3 - 
5μM, line 4 - 10 μM, and line 5 - 20 μM LY294002. Lines – theoretical results. Points - 
experimental data: 400 μM PIP2 in the assay (Vlahos et al., 1994). (D): Dose dependence of ADP 
production inhibition on BEZ235 (line 1) and LY294002 (line 2) concentrations. Lines - theoretical 
calculations, points - experimental data on the inhibition of ADP production by PI3Kα 
(p85/p110α complex) on BEZ235 (circles) and LY294002 (squares) concentrations: 0.5 μATP, 10 
μM PIP2, 0.4 μg/mL PI3Kα, time of reaction stopping t=60 min in the ADP-release assay (Maira 
et al., 2008).   
 
Fig. 8. Dependence of IC50 for BEZ235 (A) and LY294002 (B) for PI3K on ATP concentration 
obtained based on dose dependence of ADP production on inhibitor concentration. Lines – 
theoretical  IC50 dependencies for ADP production calculated according to Eq. (9) (solid lines) 
and for the reaction rate calculated by Eqs. (5) and (7) (dotted lines). Points - experimental data 
for PI3Kγ: 10 μM PIP2, 10 nM PI3Kα in the assay, reaction was terminated  after tm=120 min 
(Maira et al., 2008). 
 
Fig. 9. Dependence of reaction rate of PIP3 hydrolysis by PTEN on PIP3 concentration  at the 
different molar fractions of PIP3, X
PIP3
 given in reciprocal axes 1/V
PTEN
 and 1/PIP3. Lines - 
theoretical results, points - experimental data on PTEN activity measured in phosphatidilcholin 
vesicles at X
PIP3
=0.1 (filled circle, line 1), 0.01 (open circles, line 2), 0.002 (filled squares, line 3), 
and 0.001 (open squares, line 4) (McConnachie et al., 2003). 
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